Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-07-22

Clinical Trial Update: Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the addition of rituximab to standard therapy for thrombotic thrombocytopenic purpura was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)

Snippet

Sponsor: Carelon Research | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 3 | Status: TERMINATED | Results posted: 2013-07-22